title: [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
abstract: BACKGROUND
  Primary debulking surgery and chemotherapy (paclitaxel and carboplatin) remain the standard treatment for advanced ovarian cancer. The size of the residual tumour after primary debulking surgery has proved to be an important prognostic determinant. Complete tumour debulking without any macroscopic residual disease is considered the optimal primary debulking surgery. It is not possible to perform such an aggressive operation in patients with advanced ovarian cancer due to the bad performance status and extensive disease. Neo-adjuvant chemotherapy and interval debulking surgery seem to be an effective treatment strategy in this group of patients.
  
  
  METHODS
  The retrospective analysis evaluated the efficiency of interval debulking surgery in correlation with progression-free and overall survival in patients with advanced ovarian cancer. 38 patients were treated with standard chemotherapy: paclitaxel 175 mg/m2 and carboplatin 5-6 AUC every three weeks. According to the clinical response, surgical debulking was considered, after which postoperative chemotherapy was given. Ineligible patients for interval debulking were treated with 2nd line chemotherapy.
  
  
  RESULTS
  After neo-adjuvant chemotherapy, 24 patients of the group of 38 achieved partial remission and interval debulking surgery was indicated. Optimal interval debulking surgery was performed in 12 patients, suboptimal debulking surgery in 12 patients. Of the entire group, 14 patients did not show any adequate response to the primary treatment, they did not have interval debulking surgery indicated and they were treated with 2nd line chemotherapy. Progression-free survival in patients after optimal debulking was 11 months, median overall survival was not achieved (OS > 42.5 months). Progression-free survival in patients after suboptimal debulking was 6 months and median overall survival was 33 months. Median overall survival in patients without surgical treatment was 21.5 months.
  
  
  CONCLUSIONS
  The results of the study confirm that neo-adjuvant chemotherapy with subsequent interval debulking surgery is a suitable therapeutic approach in primary inoperable patients with advanced ovarian cancer.
authors.affiliation: Lonkologická klinika LF UK, Bratislava, Slovenská republika. lickovamarcela@yahoo.com
authors.forename: M
authors.initials: M
authors.lastname: Tkácová
authors.forename: B
authors.initials: B
authors.lastname: Vertaková-Krakovská
authors.forename: B
authors.initials: B
authors.lastname: Belohorská
authors.forename: V
authors.initials: V
authors.lastname: Miskovská
authors.forename: L
authors.initials: L
authors.lastname: Helpianska
authors.forename: D
authors.initials: D
authors.lastname: Ondrus
authors.forename: M
authors.initials: M
authors.lastname: Ondrusová
authors.forename: S
authors.initials: S
authors.lastname: Spánik
authors.forename: J
authors.initials: J
authors.lastname: Svec
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D015996:Survival Rate
chemical_list: D016190:Carboplatin; D017239:Paclitaxel